Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVID-212
- Development stage
- Preclinical
- Lead developer
- AdCure Bio
- Modality
- Gene Silencing → Gene Therapies, Oncolytic Viruses → Oncolytic Therapeutics, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies
- Administration
- Intravenous
01
Overview
AVID-212 is an engineered oncolytic adenovirus developed by AdCure Bio for the treatment of solid tumors, including non-small cell lung cancer (NSCLC). It is the lead candidate from the Artificial Vectors for Intravascular Delivery (AVID) platform, which is designed to enable systemic (intravenous) administration of oncolytic viruses while avoiding neutralization by the immune system and minimizing off-target toxicity. The vector is engineered to selectively infect and replicate within tumor cells, leading to direct oncolysis and the potential induction of a systemic anti-tumor immune response. AVID-212 is currently in preclinical development and has been assigned FDA pre-IND file number PS003489.
Beyond the preview
Go deeper on AVID-212.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVID-212.